![Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling | bioRxiv Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2018/07/14/369322/F1.large.jpg)
Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling | bioRxiv
![Frontiers | Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions Frontiers | Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions](https://www.frontiersin.org/files/Articles/456001/fcell-07-00081-HTML/image_m/fcell-07-00081-g002.jpg)
Frontiers | Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
![HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML | Journal of Experimental & Clinical Cancer Research | Full Text HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02007-4/MediaObjects/13046_2021_2007_Fig2_HTML.png)
HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML | Journal of Experimental & Clinical Cancer Research | Full Text
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia | Haematologica
![A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML | Nature Communications A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-019-09917-0/MediaObjects/41467_2019_9917_Fig3_HTML.png)
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML | Nature Communications
![Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - ScienceDirect Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2352396418305449-gr7.jpg)
Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - ScienceDirect
![Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - eBioMedicine Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - eBioMedicine](https://www.thelancet.com/cms/asset/f44200bb-3f26-44b7-9d87-5e4203ff8993/gr1.jpg)
Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9 - eBioMedicine
![CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia - ScienceDirect CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S193459091500363X-gr7.jpg)
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia - ScienceDirect
![Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia | Journal of Hematology & Oncology | Full Text Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0749-y/MediaObjects/13045_2019_749_Fig1_HTML.png)
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia | Journal of Hematology & Oncology | Full Text
![Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells | Blood Cancer Journal Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-018-0165-5/MediaObjects/41408_2018_165_Fig1_HTML.png)